Rheumatoid Arthritis

Investigators gathered data from vulnerable populations with rheumatic disease regarding their thoughts and opinions on the COVID-19 virus.

In this retrospective study, investigators analyzed patients with newly diagnosed RA, to determine if short-term, low doses (< 10 mg/day) of prednisone would help DAS28-ESR score.

Daniel Hernandez, MD, and Esteban Rivera discuss the study, “Social Listening: Factual vs. Misinformation YouTube Spanish-Language Rheumatoid Arthritis Videos,” presented at the 23rd Pan-American Conference of Rheumatology (PANLAR) 2021.

Bryant England, MD, discusses his presentation entitled, “Epidemiology of Multimorbidity in Rheumatoid Arthritis."

Test your knowledge of rheumatoid arthritis with our "Best of 2020" quiz!

John Cush, MD, discusses his upcoming lecture entitled, “Rheumatoid Arthritis: Year in Review,” which will be presented at the Congress of Clinical Rheumatology.

On this month's episode of Overdrive, Roy Fleischmann, MD, discusses the recent Pfizer press release regarding the safety of JAK inhibitors and his personal opinions on prescribing JAK inhibiting drugs to his patients.

After controlling for variables, eldery-onset rheumatoid arthritis (EORA) was not indicative of changes in Clinical Disease Activity Index (CDAI) scores over time when compared with a non-EORA cohort. Further, there were no significant differences in the efficacy and safety of receiving biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).

While prevention of atherosclerotic cardiovascular disease (ASCVD) in patients with rheumatoid arthritis (RA) is advocated by recent recommendations, ASCVD prevention in patients with RA was underwhelming, according to an international audit.

Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.

Researchers from Texas determined the global prevalence of OSA using 8 unique studies involving patients with rheumatoid arthritis from around the world.

Treat-to-target remains a key strategy for the treatment of rheumatoid arthritis. However, some changes to the recommendations were made in the 2021 American College of Rheumatology Guidelines on the Management of Rheumatoid Arthritis. Check your knowledge on how to approach a treat-to-target strategy with this quiz.

Given the low prevalence of anti-Sjögren's-syndrome-related antigen A (anti-SSA) and anti–Sjögren's-syndrome-related antigen B (anti-SSB) in women with rheumatoid arthritis who would like to conceive, intensive echocardiographic screening may not be necessary.

New findings show patients with osteoarthritis and rheumatoid arthritis share comorbidities that contribute to an increased likelihood of frailty, especially in older populations.

Surprisingly, patients with rheumatoid arthritis and erectile dysfunction had a significantly decreased rate of myocardial infarction, heart failure, and death when compared with patients with rheumatoid arthritis alone.

Claire Daien, MD, discusses the safety and efficacy of ABX464, the primary and secondary endpoints, and what differentiates the medication from other rheumatoid arthritis therapies.

Methotrexate has been the mainstay treatment for mild to moderate arthritis for many years, and the recent update to the American College of Rheumatology Guidelines on the Management of Rheumatoid Arthritis aims to maximize the use of methotrexate before advancing to a biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD). With this in mind, it is important to be up-to-speed on initiating methotrexate in patients with rheumatoid arthritis. Test your knowledge with this quiz.

Test your knowledge of the treatment and management of rheumatoid arthritis (RA) with our RA quizzes.

Investigators push for messaging transparency and consistency from health care professionals in regard to arthritis medication.

The American College of Rheumatology (ACR) published its long-awaited update to the 2015 Guidelines on the Management of Rheumatoid Arthritis last week. Have you read the 2021 update yet? Test your knowledge of the most important points with our quiz.

Liana Fraenkel, MD, MPH, discusses the recent updates to the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, for which she served as part of the Core Leadership Team.

Rheumatology Network sat down with Eugen Feist, MD, to discuss the recent olokizumab data including the therapeutic prospects for olokizumab, its unique biologic mode of action, and the clinical significance of the phase III studies.

Of the 44 new recommendations, 7 were strongly recommended.

The American College of Rheumatology has updated its treatment guidelines for rheumatoid arthritis. The guideline includes 44 treatment recommendations, 7 of which are now strongly recommended.